ADVM
Adverum Biotechnologies, Inc.Company Information
- Company Name
- Adverum Biotechnologies, Inc.
- CIK
- CIK0001501756
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ADVM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ADVM
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-08
- Last sale
- 2025-12-04
- Shares purchased (TTM)
- 381,677
- Shares sold (TTM)
- 760,495
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 11,488,922
- Shares outstanding
- 23,487,000
- Ownership
- 48.92%
Earnings Market Reaction
- Filing date
- 2025-11-12
- Price on filing date
- —
- 1-month reaction
- -0.93%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 26 | 42 | 49 | 61 | 93 | 127 | 150 | 75 | 105 | 111 | 68 | 68 | ||||||
| Short Term Investments | 0 | 2 | 34 | 65 | 60 | 47 | 44 | 22 | 12 | 30 | 97 | 117 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 6 | 6 | 8 | 6 | 6 | 6 | 8 | 6 | 5 | 5 | ||||||
| Incentive To Lessee | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets Current | 29 | 48 | 89 | 131 | 161 | 179 | 199 | 103 | 125 | 147 | 169 | 191 | ||||||
| Operating Lease Right Of Use Asset | 29 | 34 | 34 | 34 | 51 | 51 | 52 | 35 | 53 | 58 | 70 | 79 | ||||||
| Property Plant And Equipment Net | 10 | 11 | 11 | 12 | 12 | 13 | 14 | 15 | 15 | 32 | 33 | 35 | ||||||
| Deferred Rent Receivables Net | - | - | - | - | 7 | 7 | - | - | - | - | - | 0 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Other Assets Noncurrent | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 72 | 96 | 138 | 180 | 234 | 254 | 268 | 156 | 197 | 241 | 276 | 308 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 12 | 5 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 2 | ||||||
| Operating Lease Liability Current | 6 | 7 | 7 | 6 | 11 | 11 | 10 | 5 | 10 | 25 | 26 | 13 | ||||||
| Liabilities Current | 45 | 31 | 25 | 23 | 28 | 22 | 22 | 20 | 29 | 45 | 46 | 32 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 83 | 85 | 86 | 86 | 63 | 63 | 64 | 69 | 65 | 66 | 71 | 94 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Liabilities | 128 | 116 | 111 | 109 | 90 | 86 | 86 | 89 | 94 | 110 | 118 | 127 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,156 | 1,143 | 1,141 | 1,138 | 1,135 | 1,132 | 1,127 | 1,004 | 999 | 995 | 990 | 986 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -0 | -1 | -1 | -1 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -1,211 | -1,163 | -1,114 | -1,067 | -990 | -963 | -945 | -936 | -896 | -863 | -832 | -803 | ||||||
| Stockholders Equity | -56 | -20 | 26 | 71 | 108 | 137 | 164 | 67 | 103 | 131 | 158 | 182 | ||||||
| Liabilities And Stockholders Equity | 72 | 96 | 138 | 180 | 234 | 254 | 268 | 156 | 197 | 241 | 276 | 308 | ||||||
| Common Stock Shares Issued | - | - | - | 21 | - | - | - | 10 | - | - | - | 10 | ||||||
| Shares Outstanding | - | - | - | 21 | - | - | - | 10 | - | - | - | 10 | ||||||
| Common Stock Shares Authorized | - | - | - | 300 | - | - | - | 300 | - | - | - | 300 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | 5 | - | - | - | 5 | - | - | - | 5 | ||||||
| Preferred Stock Shares Issued | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAdverum Biotechnologies, Inc. (ADVM) — SEC Financial Statements & Analysis
Adverum Biotechnologies, Inc. (ADVM) is a biological products, (no diagnostic substances) company, incorporated in DE. Adverum Biotechnologies, Inc. trades on Nasdaq as: ADVM. Adverum Biotechnologies, Inc. (ADVM)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-12. Based on that filing, On profitability, Adverum Biotechnologies, Inc. posts an operating margin of -17513.20%, a net margin of -16949.20%, a Return on Equity (ROE) of -702.41%, a Return on Assets (ROA) of -120.47%, and a Return on Invested Capital (ROIC) of -69579.50%. Per share, it reports EPS of $-7.87, diluted EPS of $-7.87, free cash flow per share of $-5.89, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 55.73% year-over-year, and EPS growth of 38.42% year-over-year. On the balance sheet, it maintains a current ratio of 0.65x, a quick ratio of 0.58x, working capital of $-15.84M, a debt-to-equity ratio of -2.30x, a debt ratio of 1.77, free cash flow of $-138.44M (TTM), and net debt of $-28.04M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-7.87
- ROE TTM
- -702.41%
- ROA TTM
- -120.47%
- Debt To Equity
- -2.30x
- Free Cash Flow TTM
- $-138.44M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Adverum Biotechnologies, Inc. in?
Adverum Biotechnologies, Inc. (ADVM) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ADVM trade on?
Adverum Biotechnologies, Inc. (ADVM) trades on the Nasdaq.
Where is Adverum Biotechnologies, Inc. incorporated?
Adverum Biotechnologies, Inc. is incorporated in DE.
When was Adverum Biotechnologies, Inc. (ADVM)'s most recent SEC filing?
Adverum Biotechnologies, Inc. (ADVM)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-12.
What is ADVM's EPS (earnings per share)?
Adverum Biotechnologies, Inc. (ADVM)'s trailing twelve month EPS is $-7.87 as of 2025-09-30.
What is ADVM's ROE (return on equity)?
Adverum Biotechnologies, Inc. (ADVM)'s trailing twelve month Return on Equity (ROE) is -702.41% as of 2025-09-30.
What is ADVM's ROA (return on assets)?
Adverum Biotechnologies, Inc. (ADVM)'s trailing twelve month Return on Assets (ROA) is -120.47% as of 2025-09-30.
What is ADVM's ROIC (return on invested capital)?
Adverum Biotechnologies, Inc. (ADVM)'s trailing twelve month Return on Invested Capital (ROIC) is -69579.50% as of 2024-12-31.